| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.
|
Proc Natl Acad Sci U S A
|
2007
|
9.82
|
|
2
|
Targeting microRNAs in cancer: rationale, strategies and challenges.
|
Nat Rev Drug Discov
|
2010
|
6.07
|
|
3
|
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
|
Blood
|
2009
|
5.87
|
|
4
|
Chipping away at the chip bias: RNA degradation in microarray analysis.
|
Nat Genet
|
2003
|
5.67
|
|
5
|
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
|
Blood
|
2006
|
5.40
|
|
6
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
|
7
|
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.
|
Blood
|
2008
|
5.23
|
|
8
|
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
|
J Clin Oncol
|
2012
|
4.34
|
|
9
|
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.
|
Cell
|
2010
|
4.07
|
|
10
|
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
|
Proc Natl Acad Sci U S A
|
2010
|
3.86
|
|
11
|
MicroRNA fingerprints during human megakaryocytopoiesis.
|
Proc Natl Acad Sci U S A
|
2006
|
3.80
|
|
12
|
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
|
Cancer Cell
|
2005
|
3.44
|
|
13
|
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
|
Blood
|
2007
|
3.41
|
|
14
|
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations.
|
J Clin Invest
|
2006
|
3.27
|
|
15
|
MicroRNA 29b functions in acute myeloid leukemia.
|
Blood
|
2009
|
3.19
|
|
16
|
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2011
|
3.01
|
|
17
|
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
J Clin Oncol
|
2008
|
2.98
|
|
18
|
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
|
J Clin Invest
|
2007
|
2.91
|
|
19
|
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
|
J Clin Oncol
|
2006
|
2.87
|
|
20
|
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2009
|
2.78
|
|
21
|
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
|
Cancer Discov
|
2013
|
2.74
|
|
22
|
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
|
Blood
|
2012
|
2.65
|
|
23
|
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
|
J Clin Oncol
|
2007
|
2.64
|
|
24
|
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia.
|
Nat Genet
|
2005
|
2.63
|
|
25
|
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
|
Blood
|
2008
|
2.63
|
|
26
|
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells.
|
Immunity
|
2006
|
2.56
|
|
27
|
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.
|
Blood
|
2011
|
2.50
|
|
28
|
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
|
Blood
|
2008
|
2.46
|
|
29
|
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
|
Blood
|
2004
|
2.37
|
|
30
|
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.
|
Cancer Cell
|
2010
|
2.37
|
|
31
|
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
|
Blood
|
2008
|
2.24
|
|
32
|
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.
|
J Natl Compr Canc Netw
|
2011
|
2.24
|
|
33
|
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
|
Blood
|
2003
|
2.23
|
|
34
|
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
|
Blood
|
2008
|
2.20
|
|
35
|
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
|
Blood
|
2013
|
2.16
|
|
36
|
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
|
Blood
|
2007
|
2.15
|
|
37
|
Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review.
|
Br J Haematol
|
2007
|
2.08
|
|
38
|
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Blood
|
2010
|
2.03
|
|
39
|
Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation.
|
Cancer Cell
|
2012
|
2.01
|
|
40
|
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
|
Blood
|
2012
|
1.97
|
|
41
|
Acute myeloid leukemia.
|
J Natl Compr Canc Netw
|
2012
|
1.96
|
|
42
|
CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.
|
Blood
|
2009
|
1.94
|
|
43
|
Leukocytoreduction for acute leukemia.
|
Ther Apher
|
2002
|
1.88
|
|
44
|
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
|
J Clin Oncol
|
2012
|
1.79
|
|
45
|
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
|
Blood
|
2012
|
1.77
|
|
46
|
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.
|
Blood
|
2006
|
1.74
|
|
47
|
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.
|
Blood
|
2005
|
1.73
|
|
48
|
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
|
J Clin Invest
|
2013
|
1.72
|
|
49
|
Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.
|
Cancer Res
|
2005
|
1.69
|
|
50
|
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
|
Blood
|
2007
|
1.64
|
|
51
|
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
J Clin Oncol
|
2009
|
1.63
|
|
52
|
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
|
Nucleic Acids Res
|
2007
|
1.62
|
|
53
|
Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.61
|
|
54
|
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.
|
Blood
|
2012
|
1.59
|
|
55
|
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2010
|
1.59
|
|
56
|
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2008
|
1.57
|
|
57
|
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.
|
J Clin Oncol
|
2012
|
1.56
|
|
58
|
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
|
Blood
|
2005
|
1.56
|
|
59
|
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
|
Blood
|
2012
|
1.51
|
|
60
|
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia.
|
Cancer Res
|
2008
|
1.49
|
|
61
|
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Blood
|
2010
|
1.49
|
|
62
|
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
|
Cancer
|
2013
|
1.48
|
|
63
|
Acute Myeloid Leukemia: Biologic, Prognostic, and Therapeutic Insights.
|
Oncology (Williston Park)
|
2016
|
1.46
|
|
64
|
Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.
|
J Control Release
|
2006
|
1.45
|
|
65
|
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.43
|
|
66
|
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
|
Blood
|
2010
|
1.41
|
|
67
|
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia.
|
Proc Natl Acad Sci U S A
|
2009
|
1.39
|
|
68
|
Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.
|
Mol Pharm
|
2009
|
1.37
|
|
69
|
Prevention and treatment of cancer-related infections.
|
J Natl Compr Canc Netw
|
2008
|
1.36
|
|
70
|
In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.
|
Haematologica
|
2013
|
1.36
|
|
71
|
Regulation of acute graft-versus-host disease by microRNA-155.
|
Blood
|
2012
|
1.35
|
|
72
|
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.
|
Blood
|
2012
|
1.33
|
|
73
|
Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
|
Blood
|
2012
|
1.31
|
|
74
|
Curcumin is a potent DNA hypomethylation agent.
|
Bioorg Med Chem Lett
|
2008
|
1.31
|
|
75
|
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Blood
|
2010
|
1.30
|
|
76
|
NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.
|
J Clin Invest
|
2011
|
1.30
|
|
77
|
Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method.
|
Rapid Commun Mass Spectrom
|
2006
|
1.30
|
|
78
|
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
|
Clin Cancer Res
|
2013
|
1.30
|
|
79
|
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2009
|
1.29
|
|
80
|
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.
|
Biol Blood Marrow Transplant
|
2011
|
1.29
|
|
81
|
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
|
Blood
|
2003
|
1.26
|
|
82
|
Acute myeloid leukemia, version 2.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.26
|
|
83
|
Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status.
|
PLoS Genet
|
2013
|
1.24
|
|
84
|
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
|
J Clin Oncol
|
2012
|
1.23
|
|
85
|
The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.
|
Blood
|
2012
|
1.23
|
|
86
|
Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry.
|
J Am Soc Mass Spectrom
|
2004
|
1.22
|
|
87
|
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
|
J Clin Oncol
|
2010
|
1.20
|
|
88
|
Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.
|
Blood
|
2011
|
1.19
|
|
89
|
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
|
Haematologica
|
2010
|
1.17
|
|
90
|
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
|
Clin Cancer Res
|
2008
|
1.17
|
|
91
|
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
|
Blood
|
2008
|
1.16
|
|
92
|
Epigenetics in acute myeloid leukemia.
|
Semin Oncol
|
2008
|
1.16
|
|
93
|
Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.
|
Clin Cancer Res
|
2005
|
1.16
|
|
94
|
Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling.
|
Cancer
|
2011
|
1.16
|
|
95
|
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.
|
J Clin Oncol
|
2013
|
1.15
|
|
96
|
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
|
Blood
|
2013
|
1.14
|
|
97
|
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.
|
Curr Opin Oncol
|
2008
|
1.14
|
|
98
|
Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.
|
Blood
|
2012
|
1.13
|
|
99
|
Molecular signatures in acute myeloid leukemia.
|
Curr Opin Hematol
|
2009
|
1.13
|
|
100
|
Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.
|
Biol Blood Marrow Transplant
|
2009
|
1.13
|
|
101
|
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
|
J Exp Med
|
2013
|
1.13
|
|
102
|
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
|
Blood
|
2008
|
1.12
|
|
103
|
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.
|
Blood
|
2011
|
1.12
|
|
104
|
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.
|
Cancer
|
2007
|
1.11
|
|
105
|
Acute myeloid leukemia.
|
J Natl Compr Canc Netw
|
2011
|
1.09
|
|
106
|
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity.
|
J Clin Invest
|
2013
|
1.08
|
|
107
|
C/EBPα and DEK coordinately regulate myeloid differentiation.
|
Blood
|
2012
|
1.08
|
|
108
|
A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.
|
Pharm Res
|
2009
|
1.07
|
|
109
|
Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
|
Blood
|
2007
|
1.07
|
|
110
|
Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability.
|
Blood
|
2012
|
1.07
|
|
111
|
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
|
Cancer
|
2012
|
1.06
|
|
112
|
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
|
J Pharmacol Exp Ther
|
2007
|
1.06
|
|
113
|
miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model.
|
Proc Natl Acad Sci U S A
|
2012
|
1.05
|
|
114
|
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
|
Clin Cancer Res
|
2008
|
1.05
|
|
115
|
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.
|
J Pharmacol Exp Ther
|
2005
|
1.04
|
|
116
|
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
|
Blood
|
2012
|
1.04
|
|
117
|
Potential of microRNAs for cancer diagnostics, prognostication and therapy.
|
Curr Opin Oncol
|
2012
|
1.03
|
|
118
|
Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing.
|
J Control Release
|
2009
|
1.02
|
|
119
|
TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia.
|
Blood
|
2009
|
1.01
|
|
120
|
Liquid chromatography mass spectrometry profiling of histones.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2007
|
1.00
|
|
121
|
Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse.
|
Haematologica
|
2011
|
1.00
|
|
122
|
Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
|
Cancer Res
|
2014
|
1.00
|
|
123
|
Modulation of DNA methylation by a sesquiterpene lactone parthenolide.
|
J Pharmacol Exp Ther
|
2009
|
0.99
|
|
124
|
Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.
|
Blood
|
2013
|
0.99
|
|
125
|
Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
|
J Pharmacol Exp Ther
|
2005
|
0.99
|
|
126
|
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
|
Br J Haematol
|
2010
|
0.99
|
|
127
|
A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices.
|
Pharm Res
|
2006
|
0.99
|
|
128
|
Targeting epigenetic changes in acute myeloid leukemia.
|
Clin Adv Hematol Oncol
|
2005
|
0.98
|
|
129
|
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
|
Cancer Chemother Pharmacol
|
2008
|
0.98
|
|
130
|
Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.
|
Br J Haematol
|
2013
|
0.97
|
|
131
|
Transcriptional control of human T-BET expression: the role of Sp1.
|
Eur J Immunol
|
2007
|
0.96
|
|
132
|
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.
|
Blood
|
2010
|
0.96
|
|
133
|
Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
|
J Hematol Oncol
|
2013
|
0.96
|
|
134
|
The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele.
|
Blood
|
2008
|
0.96
|
|
135
|
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
|
Leuk Lymphoma
|
2012
|
0.96
|
|
136
|
Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells.
|
Mol Pharm
|
2007
|
0.95
|
|
137
|
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
|
Clin Cancer Res
|
2008
|
0.95
|
|
138
|
Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry.
|
AAPS J
|
2011
|
0.95
|
|
139
|
Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
|
Blood
|
2013
|
0.94
|
|
140
|
A Scalable, Flexible Workflow for MethylCap-Seq Data Analysis.
|
IEEE Int Workshop Genomic Signal Process Stat
|
2011
|
0.94
|
|
141
|
Histone H4 N-terminal acetylation in Kasumi-1 cells treated with depsipeptide determined by acetic acid-urea polyacrylamide gel electrophoresis, amino acid coded mass tagging, and mass spectrometry.
|
J Proteome Res
|
2007
|
0.94
|
|
142
|
Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2005
|
0.94
|
|
143
|
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
|
Leuk Res
|
2006
|
0.93
|
|
144
|
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
|
Clin Cancer Res
|
2006
|
0.92
|
|
145
|
Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification.
|
Haematologica
|
2013
|
0.91
|
|
146
|
Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia.
|
Proc Natl Acad Sci U S A
|
2012
|
0.91
|
|
147
|
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.
|
Biol Blood Marrow Transplant
|
2008
|
0.91
|
|
148
|
Methods for high-throughput MethylCap-Seq data analysis.
|
BMC Genomics
|
2012
|
0.91
|
|
149
|
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.
|
Proc Natl Acad Sci U S A
|
2014
|
0.91
|
|
150
|
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Haematologica
|
2011
|
0.90
|
|
151
|
CD94 defines phenotypically and functionally distinct mouse NK cell subsets.
|
J Immunol
|
2009
|
0.90
|
|
152
|
Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry.
|
Anal Biochem
|
2009
|
0.90
|
|
153
|
Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.
|
Proteomics
|
2009
|
0.90
|
|
154
|
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
|
Blood
|
2012
|
0.90
|
|
155
|
Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.
|
Blood
|
2012
|
0.90
|
|
156
|
Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.
|
Blood
|
2013
|
0.90
|
|
157
|
Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia.
|
Proteomics
|
2010
|
0.89
|
|
158
|
New targets of therapy in T-cell lymphomas.
|
Curr Drug Targets
|
2010
|
0.89
|
|
159
|
Molecular prognostic factors in cytogenetically normal acute myeloid leukemia.
|
Expert Rev Hematol
|
2012
|
0.88
|
|
160
|
Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
|
Mol Pharm
|
2010
|
0.87
|
|
161
|
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.
|
Blood
|
2014
|
0.87
|
|
162
|
Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
|
Anticancer Res
|
2006
|
0.87
|
|
163
|
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia.
|
Leuk Res
|
2011
|
0.87
|
|
164
|
Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity.
|
Mol Pharm
|
2012
|
0.87
|
|
165
|
Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry.
|
Anal Biochem
|
2006
|
0.87
|
|
166
|
Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons.
|
Anal Chem
|
2013
|
0.87
|
|
167
|
5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer).
|
Biochem Biophys Res Commun
|
2006
|
0.86
|
|
168
|
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
|
Clin Cancer Res
|
2012
|
0.86
|
|
169
|
New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.
|
Genes Chromosomes Cancer
|
2012
|
0.86
|
|
170
|
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
|
J Clin Invest
|
2014
|
0.86
|
|
171
|
Enrichment-based DNA methylation analysis using next-generation sequencing: sample exclusion, estimating changes in global methylation, and the contribution of replicate lanes.
|
BMC Genomics
|
2012
|
0.86
|
|
172
|
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.86
|
|
173
|
Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia.
|
Curr Opin Hematol
|
2015
|
0.85
|
|
174
|
Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma.
|
Melanoma Res
|
2005
|
0.85
|
|
175
|
Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.
|
Pharm Res
|
2009
|
0.85
|
|
176
|
Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid.
|
Int J Pharm
|
2010
|
0.85
|
|
177
|
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
|
Blood
|
2012
|
0.84
|
|
178
|
A novel liposomal formulation of flavopiridol.
|
Int J Pharm
|
2008
|
0.84
|
|
179
|
Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry.
|
AAPS J
|
2006
|
0.83
|
|
180
|
A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application.
|
AAPS J
|
2010
|
0.83
|
|
181
|
Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.
|
Invest Ophthalmol Vis Sci
|
2003
|
0.83
|
|
182
|
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).
|
Haematologica
|
2013
|
0.83
|
|
183
|
Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood.
|
Rapid Commun Mass Spectrom
|
2003
|
0.82
|
|
184
|
Purification, identification, and cloning of lysoplasmalogenase, the enzyme that catalyzes hydrolysis of the vinyl ether bond of lysoplasmalogen.
|
J Biol Chem
|
2011
|
0.82
|
|
185
|
The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis.
|
PLoS One
|
2011
|
0.82
|
|
186
|
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.
|
Am J Hematol
|
2005
|
0.81
|
|
187
|
Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.
|
AAPS J
|
2010
|
0.80
|
|
188
|
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.80
|
|
189
|
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.
|
AAPS J
|
2012
|
0.80
|
|
190
|
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.
|
Br J Haematol
|
2014
|
0.79
|
|
191
|
Characterization of leukemia-associated Rho guanine nucleotide exchange factor (LARG) expression during murine development.
|
Cell Tissue Res
|
2003
|
0.79
|
|
192
|
Simultaneous metabolic labeling of cells with multiple amino acids: Localization and dynamics of histone acetylation and methylation.
|
Proteomics Clin Appl
|
2007
|
0.79
|
|
193
|
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
|
Leuk Res
|
2010
|
0.78
|
|
194
|
Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers.
|
J Natl Compr Canc Netw
|
2014
|
0.78
|
|
195
|
Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.
|
J Clin Invest
|
2016
|
0.78
|
|
196
|
Efficient delivery of antisense oligodeoxyribonucleotide g3139 by human serum albumin-coated liposomes.
|
Mol Pharm
|
2009
|
0.78
|
|
197
|
Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox.
|
J Clin Oncol
|
2004
|
0.77
|
|
198
|
Acute myeloid leukemia.
|
J Natl Compr Canc Netw
|
2008
|
0.77
|
|
199
|
Fever and neutropenia clinical practice guidelines.
|
J Natl Compr Canc Netw
|
2004
|
0.77
|
|
200
|
Statistical methods for detecting differentially methylated regions based on MethylCap-seq data.
|
Brief Bioinform
|
2015
|
0.76
|
|
201
|
Epigenetic priming: the target?
|
Blood
|
2011
|
0.76
|
|
202
|
Determination of cellular uptake and intracellular levels of Cenersen (Aezea(®), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells.
|
J Pharm Biomed Anal
|
2012
|
0.76
|
|
203
|
Acute myeloid leukemia. Introduction.
|
Semin Oncol
|
2008
|
0.76
|
|
204
|
Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase.
|
Drug Metab Dispos
|
2008
|
0.76
|
|
205
|
Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2006
|
0.76
|
|
206
|
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.76
|
|
207
|
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
|
Leuk Lymphoma
|
2013
|
0.75
|
|
208
|
Disulfide-linked liposomes: effective delivery vehicle for Bcl-2 antisense oligodeoxyribonucleotide G3139.
|
Anticancer Res
|
2010
|
0.75
|
|
209
|
Reply to "rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases". Haematologica 2014;99(2):e20-21.
|
Haematologica
|
2014
|
0.75
|
|
210
|
CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
|
Mol Pharm
|
2015
|
0.75
|
|
211
|
A 75-year-old woman with thoracic spinal cord compression and chloroma (granulocytic sarcoma).
|
Semin Oncol
|
2012
|
0.75
|
|
212
|
Reply to K. Orendi et al.
|
J Clin Oncol
|
2013
|
0.75
|
|
213
|
New approaches in acute myeloid leukemia.
|
Best Pract Res Clin Haematol
|
2008
|
0.75
|
|
214
|
Treatment of Acute Lymphoblastic Leukemia in Adults: Applying Lessons Learned in Children.
|
Oncology (Williston Park)
|
2016
|
0.75
|
|
215
|
Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
|
J Exp Med
|
2017
|
0.75
|
|
216
|
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.75
|